86558 Federal Register / Vol. 85, No. 250 / Wednesday, December 30, 2020 / Notices 

TABLE 2—REGISTRANT OF CANCELLED PRODUCTS

EPA company No. Company name and address 

2596 ................................................ The Hartz Mountain Corporation, 400 Plaza Drive, Seacaucus, NJ 07094. 

III. Summary of Public Comments 

Received and Agency Response to 

Comments 

During the 30-day public comment 

period provided, EPA received no 

comments in response to the August 6, 

2020 Federal Register notice 

announcing the Agency’s receipt of the 

request for voluntary cancellation of the 

products listed in Table 1 of Unit II. 

IV. Cancellation Order 

Pursuant to FIFRA section 6(f) (7 

U.S.C. 136d(f)), EPA hereby approves 

the requested cancellation of the 

registrations identified in Table 1 of 

Unit II. Accordingly, the Agency hereby 

orders that the product registrations 

identified in Table 1 of Unit II. are 

canceled. The effective date of the 

cancellations that are the subject of this 

notice is December 30, 2020. Any 

distribution, sale, or use of existing 

stocks of the products identified in 

Table 1 of Unit II. in a manner 

inconsistent with any of the provisions 

for disposition of existing stocks set 

forth in Unit VI. will be a violation of 

FIFRA. 

V. What is the Agency’s authority for 

taking this action? 

Section 6(f)(1) of FIFRA (7 U.S.C. 

136d(f)(1)) provides that a registrant of 

a pesticide product may at any time 

request that any of its pesticide 

registrations be canceled or amended to 

terminate one or more uses. FIFRA 

further provides that, before acting on 

the request, EPA must publish a notice 

of receipt of any such request in the 

Federal Register. Thereafter, following 

the public comment period, the EPA 

Administrator may approve such a 

request. The notice of receipt for this 

action was published for comment in 

the Federal Register of August 6, 2020 

((volume 85 number 152) (FRL–10012– 

80)). The comment period closed on 

September 8, 2020. 

VI. Provisions for Disposition of 

Existing Stocks 

Existing stocks are those stocks of 

registered pesticide products that are 

currently in the United States and that 

were packaged, labeled, and released for 

shipment prior to the effective date of 

the cancellation action. The existing 

stocks provisions for the products 

subject to this order are as follows. 

Hartz may not ‘‘release for shipment,’’ 

as that term is defined by 40 CFR 152.3, 

any product under EPA Reg. Nos. 2596– 

78 and 2596–79 (dust products) as of 

December 30, 2020 and may not sell or 

distribute existing stocks of its dust 

products after March 31, 2021, except 

for export consistent with FIFRA section 

17 (7 U.S.C. 136o) or for proper 

disposal. Hartz may sell or distribute 

existing stocks of EPA Reg. No. 2596–63 

(cat collar) until exhausted. 

Persons other than the registrants may 

sell, distribute, or use existing stocks of 

canceled products until supplies are 

exhausted, provided that such sale, 

distribution, or use is consistent with 

the terms of the previously approved 

labeling on, or that accompanied, the 

canceled products. 

Authority: 7 U.S.C. 136 et seq. 

Dated: November 19, 2020. 

Mary Reaves, 

Acting Director, Pesticide Re-Evaluation 

Division, Office of Pesticide Programs. 

[FR Doc. 2020–28827 Filed 12–29–20; 8:45 am] 

BILLING CODE 6560–50–P 

ENVIRONMENTAL PROTECTION 

AGENCY 

[EPA–HQ–OPPT–2019–0236; FRL–10017– 

18] 

n-Methylpyrrolidone (NMP); Final Toxic 

Substances Control Act (TSCA) Risk 

Evaluation; Notice of Availability 

AGENCY: Environmental Protection 

Agency (EPA). 

ACTION: Notice. 

SUMMARY: The Environmental Protection 

Agency (EPA) is announcing the 

availability of the final Toxic 

Substances Control Act (TSCA) risk 

evaluation of n-Methylpyrrolidone 

(NMP). The purpose of conducting risk 

evaluations under TSCA is to determine 

whether a chemical substance presents 

an unreasonable risk of injury to health 

or the environment under the 

conditions of use, including an 

unreasonable risk to a relevant 

potentially exposed or susceptible 

subpopulation, without consideration of 

costs or other nonrisk factors. EPA has 

determined that specific conditions of 

use of NMP present an unreasonable 

risk of injury to health. For those 

conditions of use for which EPA has 

found an unreasonable risk, EPA must 

take regulatory action to address that 

unreasonable risk through risk 

management measures enumerated in 

TSCA. EPA has also determined that 

specific conditions of use do not present 

unreasonable risk of injury to health or 

the environment. For those conditions 

of use for which EPA has found no 

unreasonable risk to health or the 

environment, the Agency’s 

determination is a final Agency action 

and is issued via order in the risk 

evaluation. 

ADDRESSES: The docket for this action, 

identified by docket identification (ID) 

number EPA–HQ–OPPT–2019–0236, is 

available online at http://

www.regulations.gov or in-person at the 

Office of Pollution Prevention and 

Toxics Docket (OPPT Docket), 

Environmental Protection Agency 

Docket Center (EPA/DC), West William 

Jefferson Clinton Bldg., Rm. 3334, 1301 

Constitution Ave. NW, Washington, DC. 

The Public Reading Room is open from 

8:30 a.m. to 4:30 p.m., Monday through 

Friday, excluding legal holidays. The 

telephone number for the Public 

Reading Room is (202) 566–1744, and 

the telephone number for the OPPT 

Docket is (202) 566–0280. 

Due to the public health concerns 

related to COVID–19, the EPA Docket 

Center (EPA/DC) and Public Reading 

Room are closed to visitors with limited 

exceptions. The EPA/DC staff continue 

to provide remote customer service via 

email, phone, and webform. For the 

latest status information on EPA/DC 

services and docket access, visit https:// 

www.epa.gov/dockets. 

FOR FURTHER INFORMATION CONTACT: 

For technical information contact: 

Seema Schappelle, Office of Pollution 

Prevention and Toxics (7403M), 

Environmental Protection Agency, 1200 

Pennsylvania Ave. NW, Washington, DC 

20460–0001; telephone number: (202) 

564–8006; email address: 

schappelle.seema@epa.gov. 

For general information contact: The 

TSCA-Hotline, ABVI-Goodwill, 422 

South Clinton Ave., Rochester, NY 

14620; telephone number: (202) 554– 

1404; email address: TSCA-Hotline@

epa.gov. 

SUPPLEMENTARY INFORMATION: 

Federal Register / Vol. 85, No. 250 / Wednesday, December 30, 2020 / Notices 86559 

I. General Information 

A. Does this action apply to me? 

This action is directed to the public 

in general. This action may be of 

interest to persons who are or may be 

interested in risk evaluations of 

chemical substances under TSCA, 15 

U.S.C. 2601 et seq. Since other entities 

may also be interested in this final risk 

evaluation, the EPA has not attempted 

to describe all the specific entities that 

may be affected by this action. 

B. What is EPA’s authority for taking 

this action? 

TSCA section 6, 15 U.S.C. 2605, 

requires EPA to conduct risk 

evaluations to ‘‘determine whether a 

chemical substance presents an 

unreasonable risk of injury to health or 

the environment, without consideration 

of costs or other nonrisk factors, 

including an unreasonable risk to a 

potentially exposed or susceptible 

subpopulation identified as relevant to 

the risk evaluation by the 

Administrator, under the conditions of 

use.’’ 15 U.S.C. 2605(b)(4)(A). TSCA 

sections 6(b)(4)(A) through (H) 

enumerate the deadlines and minimum 

requirements applicable to this process, 

including provisions that provide 

instruction on chemical substances that 

must undergo evaluation, the minimum 

components of a TSCA risk evaluation, 

and the timelines for public comment 

and completion of the risk evaluation. 

TSCA also requires that EPA operate in 

a manner that is consistent with the best 

available science, make decisions based 

on the weight of the scientific evidence 

and consider reasonably available 

information. 15 U.S.C. 2625(h), (i), and 

(k). TSCA section 6(i) directs that a 

determination of ‘‘no unreasonable risk’’ 

shall be issued by order and considered 

to be a final Agency action, while a 

determination of ‘‘unreasonable risk’’ is 

not considered to be a final Agency 

action. 15 U.S.C. 2605(i). 

The statute identifies the minimum 

components for all chemical substance 

risk evaluations. For each risk 

evaluation, EPA must publish a 

document that outlines the scope of the 

risk evaluation to be conducted, which 

includes the hazards, exposures, 

conditions of use, and the potentially 

exposed or susceptible subpopulations 

that EPA expects to consider. 15 U.S.C. 

2605(b)(4)(D). The statute further 

provides that each risk evaluation must 

also: (1) Integrate and assess available 

information on hazards and exposures 

for the conditions of use of the chemical 

substance, including information that is 

relevant to specific risks of injury to 

health or the environment and 

information on relevant potentially 

exposed or susceptible subpopulations; 

(2) describe whether aggregate or 

sentinel exposures were considered and 

the basis for that consideration; (3) take 

into account, where relevant, the likely 

duration, intensity, frequency, and 

number of exposures under the 

conditions of use; and (4) describe the 

weight of the scientific evidence for the 

identified hazards and exposures. 15 

U.S.C. 2605(b)(4)(F)(i) through (ii) and 

(iv) through (v). Each risk evaluation 

must not consider costs or other nonrisk 

factors. 15 U.S.C. 2605(b)(4)(F)(iii). 

The statute requires that the risk 

evaluation process be completed within 

a specified timeframe and provide an 

opportunity for public comment on a 

draft risk evaluation prior to publishing 

a final risk evaluation. 15 U.S.C. 

2605(b)(4) 

Subsection 5.1.1 of the final risk 

evaluation for NMP constitutes the 

order required under TSCA section 

6(i)(1), and the ‘‘no unreasonable risk’’ 

determinations in that subsection are 

considered to be a final Agency action 

effective on the date of issuance of the 

order. In conducting risk evaluations, 

‘‘EPA will determine whether the 

chemical substance presents an 

unreasonable risk of injury to health or 

the environment under each condition 

of use within the scope of the risk 

evaluation . . . .’’ 40 CFR 702.47. Under 

EPA’s implementing regulations, ‘‘[a] 

determination by EPA that the chemical 

substance, under one or more of the 

conditions of use within the scope of 

the risk evaluation, does not present an 

unreasonable risk of injury to health or 

the environment will be issued by order 

and considered to be a final Agency 

action, effective on the date of issuance 

of the order.’’ 40 CFR 702.49(d). For 

purposes of TSCA section 19(a)(1)(A), 

the date of issuance of the TSCA section 

6(i)(1) order for NMP shall be at 1:00 

p.m. Eastern time (standard or daylight, 

as appropriate) on the date that is two 

weeks after the date when this notice is 

published in the Federal Register, 

which is in accordance with 40 CFR 

23.5. 

C. What action is EPA taking? 

EPA is announcing the availability of 

the risk evaluation of the chemical 

substance identified in Unit II. In this 

risk evaluation EPA has made 

unreasonable risk determinations on 

some of the conditions of use within the 

scope of the risk evaluation for this 

chemical. For those conditions of use 

for which EPA has found an 

unreasonable risk of injury to health or 

the environment, EPA must initiate 

regulatory action to address those risks 

through risk management measures 

enumerated in 15 U.S.C. 2605(a). 

EPA also is announcing the 

availability of the information required 

to be provided publicly with each risk 

evaluation, which is available online at 

http://www.regulations.gov in the 

dockets identified. 40 CFR 702.51. 

Specifically, EPA has provided: 

• The scope document and problem 

formulation (in Docket ID No. EPA–HQ– 

OPPT–2016–0743); 

• Draft risk evaluation, and final risk 

evaluation (in Docket ID No. EPA–HQ– 

OPPT–2019–0236); 

• All notices, determinations, 

findings, consent agreements, and 

orders (in Docket ID No. EPA–HQ– 

OPPT–2019–0236); 

• Any information required to be 

provided to the Agency under 15 U.S.C. 

2603 (in Docket ID No. EPA–HQ–OPPT– 

2016–0743 and Docket ID No. EPA–HQ– 

OPPT–2019–0236); 

• A nontechnical summary of the risk 

evaluation (in Docket ID No. EPA–HQ– 

OPPT–2019–0236); 

• A list of the studies, with the results 

of the studies, considered in carrying 

out each risk evaluation (Risk 

Evaluation for N-methylpyrrolidone 

(NMP)) in Docket ID No. EPA–HQ– 

OPPT–2019–0236); 

• The final peer review report, 

including the response to peer review 

and public comments received during 

peer review (in Docket ID No. EPA–HQ– 

OPPT–2019–0236); and 

• Response to public comments 

received on the draft scope and the draft 

risk evaluation (in Docket ID No. EPA– 

HQ–OPPT–2019–0236). 

II. TSCA Risk Evaluation 

A. What is EPA’s risk evaluation process 

for existing chemicals under TSCA? 

The risk evaluation process is the 

second step in EPA’s existing chemical 

review process under TSCA, following 

prioritization and before risk 

management. As this chemical is one of 

the first ten chemical substances 

undergoing risk evaluation, the 

chemical substance was not required to 

go through prioritization (81 FR 91927, 

December 19, 2016) (FRL–9956–47). The 

purpose of conducting risk evaluations 

is to determine whether a chemical 

substance presents an unreasonable risk 

of injury to health or the environment 

under the conditions of use, including 

an unreasonable risk to a relevant 

potentially exposed or susceptible 

subpopulation. As part of this process, 

EPA must evaluate both hazard and 

exposure, not consider costs or other 

nonrisk factors, use reasonably available 

information and approaches in a 

86560 Federal Register / Vol. 85, No. 250 / Wednesday, December 30, 2020 / Notices 

manner that is consistent with the 

requirements in TSCA for the use of the 

best available science, and ensure 

decisions are based on the weight of the 

scientific evidence. 

The specific risk evaluation process 

that EPA has established by rule to 

implement the statutory process is set 

out in 40 CFR part 702 and summarized 

on EPA’s website at http://

www.epa.gov/assessing-and-managingchemicals-under-tsca/risk-evaluationsexisting-chemicals-under-tsca. As 

explained in the preamble to EPA’s final 

rule on procedures for risk evaluation 

(82 FR 33726, July 20, 2017) (FRL– 

9964–38), the specific regulatory 

process set out in 40 CFR part 702, 

subpart B is being followed for the first 

ten chemical substances undergoing risk 

evaluation to the maximum extent 

practicable. 

Prior to the publication of this final 

risk evaluation, a draft risk evaluation 

was subject to peer review and public 

comment. EPA reviewed the report from 

the peer review committee and public 

comments and has amended the risk 

evaluation in response to these 

comments as appropriate. The public 

comments, peer review report, and 

EPA’s response to comments is in 

Docket ID No. EPA–HQ–OPPT–2019– 

0236. Prior to the publication of the 

draft risk evaluation, EPA made 

available the scope and problem 

formulation, and solicited public input 

on uses and exposure. EPA’s documents 

and the public comments are in Docket 

ID No. EPA–HQ–OPPT–2016–0743. 

Additionally, information about the 

scope, problem formulation, and draft 

risk evaluation phases of the TSCA risk 

evaluation for this chemical is available 

at EPA’s website at https://

www.epa.gov/assessing-and-managingchemicals-under-tsca/risk-evaluation-nmethylpyrrolidone-nmp-0. 

B. What is n-Methylpyrrolidone (NMP)? 

n-Methylpyrrolidone (CASRN 872– 

50–4), also called n-methyl-2- 

pyrrolidone, or 1-methyl-2-pyrrolidone, 

is a water-miscible, organic solvent that 

is often used as a substitute for 

halogenated solvents. NMP is widely 

used in the chemical manufacturing, 

petrochemical processing and 

electronics industries, and in 

semiconductor fabrication and lithium 

ion battery manufacturing {FMI, 2015, 

3827469}. In the commercial sector, 

NMP is primarily used for producing 

and removing paints, coatings and 

adhesives. Other applications include 

use in solvents, reagents, sealers, inks 

and grouts, industrial, commercial and 

consumer uses and disposal. CDR data 

shows that the total aggregate 

production volume for NMP decreased 

slightly from 164 to 160 million pounds 

between 2012 and 2015. 

Authority: 15 U.S.C. 2601 et seq. 

Andrew Wheeler, 

Administrator. 

[FR Doc. 2020–28872 Filed 12–29–20; 8:45 am] 

BILLING CODE 6560–50–P 

FEDERAL RESERVE SYSTEM 

Change in Bank Control Notices; 

Acquisitions of Shares of a Bank or 

Bank Holding Company 

The notificants listed below have 

applied under the Change in Bank 

Control Act (Act) (12 U.S.C. 1817(j)) and 

§ 225.41 of the Board’s Regulation Y (12 

CFR 225.41) to acquire shares of a bank 

or bank holding company. The factors 

that are considered in acting on the 

applications are set forth in paragraph 7 

of the Act (12 U.S.C. 1817(j)(7)). 

The public portions of the 

applications listed below, as well as 

other related filings required by the 

Board, if any, are available for 

immediate inspection at the Federal 

Reserve Bank(s) indicated below and at 

the offices of the Board of Governors. 

This information may also be obtained 

on an expedited basis, upon request, by 

contacting the appropriate Federal 

Reserve Bank and from the Board’s 

Freedom of Information Office at 

https://www.federalreserve.gov/foia/ 

request.htm. Interested persons may 

express their views in writing on the 

standards enumerated in paragraph 7 of 

the Act. 

Comments regarding each of these 

applications must be received at the 

Reserve Bank indicated or the offices of 

the Board of Governors, Ann E. 

Misback, Secretary of the Board, 20th 

Street and Constitution Avenue NW, 

Washington, DC 20551–0001, not later 

than January 14, 2021. 

A. Federal Reserve Bank of 

Minneapolis (Chris P. Wangen, 

Assistant Vice President), 90 Hennepin 

Avenue, Minneapolis, Minnesota 

55480–0291: 

1. Teresa L. Kuhn, Dilworth, 

Minnesota; to acquire control of voting 

shares of Bankshares of Hawley, Inc. 

(Bankshares), by becoming a trustee of 

Valley Premier Bank Employee Stock 

Ownership Plan and Trust, which owns 

Bankshares, and thereby indirectly 

owns Valley Premier Bank, all of 

Hawley, Minnesota. 

B. Federal Reserve Bank of Chicago 

(Colette A. Fried, Assistant Vice 

President) 230 South LaSalle Street, 

Chicago, Illinois 60690–1414: 

1. The Lynette G. Drake Trust, Lynette 

G. Drake and Alan D. Drake, as cotrustees, L Drake Commons LLC, Jeffrey 

Roberts, as manager, J Roberts 

Commons LLC, Lynette Drake, as 

manager; all of Bad Axe, Michigan; to 

join the Roberts Family Control Group, 

a group acting in concert, to retain 

voting shares of Northstar Financial 

Group, Inc., and thereby indirectly 

retain voting shares of Northstar Bank, 

both of Bad Axe, Michigan, and West 

Michigan Community Bank, 

Hudsonville, Michigan. 

In addition, The Jerry A. Peplinski 

Trust, Jerry A. Peplinski, as trustee, F 

Peplinski Commons LLC, Lynda 

Watchowski, as manager, J Peplinski 

Commons LLC, Frank A. Peplinski, as 

manager, D Peplinski Commons LLC, 

Jerry Peplinski, as manager, T Peplinski 

Commons LLC, David Peplinski, as 

manager, and L Watchowski Commons 

LLC, Terry Peplinski, as manager; all of 

Bad Axe, Michigan, to join the Peplinski 

Family Control Group, a group acting in 

concert, to retain voting shares of 

Northstar Financial Group, Inc., and 

thereby indirectly retain voting shares of 

Northstar Bank and West Michigan 

Community Bank. 

Board of Governors of the Federal Reserve 

System, December 23, 2020. 

Margaret McCloskey Shanks, 

Deputy Secretary of the Board. 

[FR Doc. 2020–28857 Filed 12–29–20; 8:45 am] 

BILLING CODE 6210–01–P 

FEDERAL RESERVE SYSTEM 

Agency Information Collection 

Activities: Announcement of Board 

Approval Under Delegated Authority 

and Submission to OMB 

AGENCY: Board of Governors of the 

Federal Reserve System. 

ACTION: Approval of information 

collection. 

SUMMARY: The Board of Governors of the 

Federal Reserve System (Board) has 

adopted two proposals to extend for 

three years, with revision, the Capital 

Assessments and Stress Testing Reports 

(FR Y–14A/Q/M; OMB No. 7100–0341). 

The revisions are effective for the 

December 31, 2020, as of date. 

FOR FURTHER INFORMATION CONTACT: 

Federal Reserve Board Clearance 

Officer—Nuha Elmaghrabi—Office of 

the Chief Data Officer, Board of 

Governors of the Federal Reserve 

System, Washington, DC 20551, (202) 

452–3829. Office of Management and 

Budget (OMB) Desk Officer—Shagufta 

Ahmed—Office of Information and 

Regulatory Affairs, Office of